Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827612) titled 'A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Urinary Bladder Neoplasms
Urologic Neoplasms
Receptor, Fibroblast Growth Factor, Type 3
Intervention:
Drug: Vepugratinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 2026
Target Sample Size: 161
Countries of Recruitment:
U...